Sinotherapeutics Inc.

SHSE:688247 Stock Report

Market Cap: CN¥4.9b

Sinotherapeutics Past Earnings Performance

Past criteria checks 3/6

Sinotherapeutics has been growing earnings at an average annual rate of 1.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 12.6% per year. Sinotherapeutics's return on equity is 8.9%, and it has net margins of 24.4%.

Key information

1.9%

Earnings growth rate

-1.6%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate12.6%
Return on equity8.9%
Net Margin24.4%
Next Earnings Update06 Dec 2024

Recent past performance updates

Concerns Surrounding Sinotherapeutics' (SHSE:688247) Performance

Nov 02
Concerns Surrounding Sinotherapeutics' (SHSE:688247) Performance

Recent updates

Optimistic Investors Push Sinotherapeutics Inc. (SHSE:688247) Shares Up 27% But Growth Is Lacking

Nov 08
Optimistic Investors Push Sinotherapeutics Inc. (SHSE:688247) Shares Up 27% But Growth Is Lacking

Concerns Surrounding Sinotherapeutics' (SHSE:688247) Performance

Nov 02
Concerns Surrounding Sinotherapeutics' (SHSE:688247) Performance

Revenue & Expenses Breakdown

How Sinotherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:688247 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 244491105287
30 Jun 24407924980
31 Mar 24369764879
31 Dec 23300614574
30 Sep 23274704468
30 Jun 23230764168
31 Mar 23227804268
31 Dec 22248934676
30 Sep 222711414382
30 Jun 222871384386
31 Mar 223011374396
31 Dec 2131513546104
31 Dec 203191235776
31 Dec 1913955451
31 Dec 1861-373350

Quality Earnings: 688247 has a high level of non-cash earnings.

Growing Profit Margin: 688247's current net profit margins (24.4%) are lower than last year (25.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 688247 has become profitable over the past 5 years, growing earnings by 1.9% per year.

Accelerating Growth: 688247's earnings growth over the past year (56.7%) exceeds its 5-year average (1.9% per year).

Earnings vs Industry: 688247 earnings growth over the past year (56.7%) exceeded the Pharmaceuticals industry -2.5%.


Return on Equity

High ROE: 688247's Return on Equity (8.9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies